Vaginal high risk human papillomavirus (HPV) DNA test positive
ICD-10 R87.811 is a billable code used to indicate a diagnosis of vaginal high risk human papillomavirus (hpv) dna test positive.
The ICD-10 code R87.811 is used to indicate a positive result from a vaginal high-risk human papillomavirus (HPV) DNA test. This finding is significant as high-risk HPV types are associated with the development of cervical cancer and other anogenital malignancies. The presence of high-risk HPV DNA in the vaginal sample suggests that the patient may be at increased risk for cervical dysplasia or cancer, necessitating further evaluation and management. Symptoms may not be present, as many individuals with HPV are asymptomatic. However, abnormal cervical cytology results, such as atypical squamous cells or squamous intraepithelial lesions, may accompany a positive HPV test. The clinical context often involves routine screening in women aged 30 and older, where HPV testing is performed alongside Pap smears to assess cervical health. Follow-up procedures may include colposcopy and biopsy to evaluate any cervical lesions. Accurate coding for this condition is crucial for appropriate patient management and tracking of HPV-related health outcomes.
Documentation must include the reason for HPV testing, results, and any follow-up plans.
Routine screening in women over 30, management of abnormal Pap results.
Consideration of patient history, including previous HPV infections and cervical treatments.
Acute care documentation should include the patient's presenting symptoms and any immediate interventions.
Patients presenting with abnormal vaginal bleeding or pelvic pain.
Emergency settings may require rapid assessment and referral for follow-up care.
Used when a patient is tested for high-risk HPV types during routine screening.
Document the reason for testing and the results.
Ensure that the test is linked to appropriate follow-up care.
A positive HPV DNA test indicates the presence of high-risk HPV types that may lead to cervical cancer. It is essential to follow up with appropriate screenings and potential treatments.
